CIK 0001176309 · Non-accelerated filer<br>Smaller reporting company
ORAMED PHARMACEUTICALS INC.
Sign in to watch- Ticker
- ORMP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980376008
- Phone
- 646-844-1164
- Business address
- 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY, 10036
- Former names
- Integrated Security Technologies, Inc., IGUANA VENTURES LTD
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $225,530
- in 2 filings, $226K under 10b5-1 plans
Net −$225,530. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | Gabay Avraham Chief Financial Officer | Sale 10b5-1 | −20,000 | $4.51 | $90K | 861,076 |
| 2026-10-01 | Hexter Joshua COO & CBO | Sale 10b5-1 | −30,000 | $4.51 | $135K | 1,328,130 |
| 2026-09-24 | KIDRON NADAV President and CEO | Grant or award | +349,497 | 3,771,740 | ||
| 2026-09-24 | KIDRON NADAV President and CEO | Grant or award | +368,765 | 4,140,505 | ||
| 2026-09-24 | KIDRON NADAV President and CEO | Returned to the company · Stock option (right to buy) | −196,500 | 0 | ||
| 2026-09-24 | KIDRON NADAV President and CEO | Returned to the company · Stock option (right to buy) | −190,000 | 0 | ||
| 2026-09-24 | KIDRON NADAV President and CEO | Returned to the company · Stock option (right to buy) | −49,000 | 0 | ||
| 2026-09-24 | KIDRON NADAV President and CEO | Returned to the company · Stock option (right to buy) | −97,000 | 0 | ||
| 2026-09-24 | KIDRON NADAV President and CEO | Returned to the company · Stock option (right to buy) | −150,000 | 0 | ||
| 2026-09-24 | KIDRON NADAV President and CEO | Returned to the company · Stock option (right to buy) | −107,000 | 0 | ||
| 2026-09-24 | Hexter Joshua COO & CBO | Grant or award | +75,455 | 1,148,839 | ||
| 2026-09-24 | Hexter Joshua COO & CBO | Grant or award | +209,291 | 1,358,130 | ||
| 2026-09-24 | Hexter Joshua COO & CBO | Returned to the company · Stock option (right to buy) | −50,000 | 0 | ||
| 2026-09-24 | Hexter Joshua COO & CBO | Returned to the company · Stock option (right to buy) | −50,000 | 0 | ||
| 2026-09-24 | Hexter Joshua COO & CBO | Returned to the company · Stock option (right to buy) | −36,000 | 0 | ||
| 2026-09-24 | Kidron Miriam Chief Scientific Officer | Grant or award | +208,125 | 1,341,263 | ||
| 2026-09-24 | Kidron Miriam Chief Scientific Officer | Grant or award | +209,291 | 1,550,554 | ||
| 2026-09-24 | Kidron Miriam Chief Scientific Officer | Returned to the company · Stock option (right to buy) | −104,000 | 0 | ||
| 2026-09-24 | Kidron Miriam Chief Scientific Officer | Returned to the company · Stock option (right to buy) | −100,000 | 0 | ||
| 2026-09-24 | Kidron Miriam Chief Scientific Officer | Returned to the company · Stock option (right to buy) | −69,999 | 0 |
Page 1 of 9 · 170 trades